Cetuximab sarotalocan is under clinical development by Rakuten Medical and currently in Phase II for Cutaneous Squamous Cell Carcinoma (cSCC). According to GlobalData, Phase II drugs for Cutaneous Squamous Cell Carcinoma (cSCC) have a 42% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Cetuximab sarotalocan’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Cetuximab sarotalocan overview

Cetuximab sarotalocan (Akalux) is a chimeric monoclonal antibody (IgG1), acts as anti-neoplastic agent. It is formulated as solution for intravenous drip route of administration. Akalux is indicated for the treatment of unresectable locally advanced or locally recurrent head and neck cancer.
RM-1929 is under development for the treatment of squamous cell esophageal cancer, cutaneous squamous cell carcinoma, recurrent head, neck cancer, gastric cancer and nasopharyngeal carcinoma. It is administered as an intravenous infusion. The drug candidate is a chemical conjugate of phthalocyanine dye IRDye 700DX with cetuximab. It targets EGFR. It is based on Alluminox technology platform.

Rakuten Medical overview

Rakuten Medical is a clinical-stage biotechnology company that develops first-in-class precision-targeted cancer drugs for the treatment of solid tumors. It’s lead pipeline product candidate, ASP-1929, used to treat patients with recurrent head and neck squamous cell carcinoma. ASP-1929 in combination with anti-PD1, in multiple tumor types. The company is conducting early-stage research for investigative molecules such as RM-1995. Rakuten Medical is headquartered in San Mateo, California, the US.

For a complete picture of Cetuximab sarotalocan’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.